HKHee Jung Kang

Hee Jung Kang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hee Jung Kang has a total of 184 co-authors. Here are the top co-authors by number of shared publications:

  • Chung-Gyu Park

    Department of Microbiology and Immunology, Seoul National University College of Medicine, Seoul, Korea

    12 shared publications
  • Haneulnari Lee

    Department of Laboratory Medicine, Hallym University College of Medicine and Hallym University Sacred Heart Hospital, Anyang, Republic of Korea

    12 shared publications
  • Eun Mi Park

    Department of Laboratory Medicine, Hallym University College of Medicine and Hallym University Sacred Heart Hospital, Anyang, Republic of Korea

    9 shared publications
  • Young Kyung Lee

    Department of Laboratory Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang 14068, Republic of Korea

    9 shared publications
  • Han-Sung Kim

    Department of Laboratory Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea

    7 shared publications
  • Han-Sung Kim

    Department of Laboratory Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea

    6 shared publications

Latest Publications

  • Open Access

    Xenotransfusion using red blood cells from genetically modified pigs: Current preclinical research status and clinical application prospects

    by Juhye Roh, Hee Jung Kang

    Aging of population and emerging infectious diseases increasingly threaten stable blood supply, underscoring the need for alternative blood sources. Porcine red blood cells (pRBCs) offer notable advantages over human RBCs, including morphological and physiological similarity, established pathogen‐free breeding systems, and freedom from ABO‐ and Rh‐compatibility constraints. Recent advances in gene editing have enabled triple‐knockout (TKO) pigs lacking the three major xenoantigens recognized by human natural antibodies, reviving interest in xenotransfusion as a potential solution to blood shortages. This narrative review examines preclinical and translational studies on pRBC xenotransfusion, focusing on immunological compatibility, in vivo survival, and adverse reactions across nonhuman primate (NHP) models, genetic engineering strategies, and emerging regulatory frameworks. In Old World NHP studies, TKO pRBCs corrected acute anemia but were cleared within 24–72 h, and retransfusion elicited acute hemolytic reactions from antibody formation. Rapid, multifactorial, immune‐mediated clearance of pRBCs remains the principal barrier to clinical use, currently limiting application to emergencies such as acute massive hemorrhage. Future strategies include engineering pigs that express human complement‐regulatory proteins and applying immunomodulatory regimens to prolong pRBC survival. Although a dedicated regulatory framework for xenotransfusion is still lacking, recent clearance of pig‐organ xenotransplantation trials offers important precedent. Continued progress in genetic engineering and immunosuppression may extend xenotransfusion to emergency medicine and the care of patients with rare blood types.

  • Open Access

    Defect in Sensing Human Thrombin by Porcine Endothelial Protease‐Activated Receptor‐1: Molecular Incompatibility Between Porcine PAR‐1 and Human Thrombin

    by Thi Xoan Hoang, Ju‐Young Bang, Vinh Phuoc Nguyen, Phu Chi Vu, Ik Jin Yun, Hee Jung Kang, Jae Young Kim

    Xenotransplantation, the transplantation of organs from pigs to humans, presents significant challenges due to immune rejection, which is driven by molecular incompatibilities between species. This study investigates the compatibility between human thrombin and porcine protease‐activated receptor‐1 (PAR‐1), a key regulator of both coagulation and inflammatory responses. Human thrombin activates PAR‐1 in human vascular endothelial cells, but our results demonstrate that human thrombin does not effectively activate PAR‐1 in porcine vascular endothelial cells due to differences in amino acid sequences, particularly at the thrombin cleavage site and the Hir domain. Protein‐protein docking analysis further reveals that porcine PAR‐1 forms less stable interactions with human thrombin compared to human PAR‐1, resulting in reduced activation. This molecular incompatibility likely contributes to impaired nitric oxide (NO) production, endothelial dysfunction, and increased inflammation, which are critical for the survival of transplanted organs. Additionally, experiments using the PAR‐1 inhibitor vorapaxar (Vor) show that inhibiting PAR‐1 signaling can suppress inflammatory cytokine and chemokine expression in co‐cultures of human macrophages and porcine endothelial cells. These findings suggest that selective PAR‐1 inhibitors or targeted therapies regulating thrombin‐PAR‐1 signaling may improve the success rate of xenotransplantation. However, further in vivo studies are needed to validate these findings and explore therapeutic interventions targeting thrombin‐PAR‐1 interactions to enhance xenograft survival.


  • Open Access

    Complement Activation and Hemolysis in Non-human Primates Following Transfusion of Genetically Modified Pig Red Blood Cells

    by Hee Jung Kang, Juhye Roh, Haneulnari Lee, Eun Mi Park, Hye Won Lee, Ju Young Lee, Jeong Ho Hwang, Joohyun Shim, Kimyung Choi

    Hee Jung Kang , M.D., Ph.D., Juhye Roh , M.D., Ph.D., Haneulnari Lee , M.S., Eun Mi Park , M.S., Hye Won Lee , M.S., Ju Young Lee , Ph.D., Jeong Ho Hwang , D.V.M., Ph.D., Joohyun Shim , Ph.D., and Kimyung Choi , Ph.D.. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2024.0443


  • Open Access

    Investigation of the efficacy and safety of wild- type and triple-gene knockout pig RBC transfusions in nonhuman primates

    by Juhye Roh, Jeong Ho Hwang, Sangkeun Park, Haneulnari Lee, Eun Mi Park, Hye Won Lee, Ju Young Lee, Joohyun Shim, Kimyung Choi, Hee Jung Kang

    Introduction: Decreasing rates of blood donation and close margins between blood supply and demand pose challenges in healthcare. Genetically engineered pig red blood cells (pRBCs) have been explored as alternatives to human RBCs for transfusion, and triple-gene knockout (TKO) modification improves the compatibility of pRBCs with human blood in vitro. In this study, we assessed the efficacy and risks of transfusing wild-type (WT)- and TKO-pRBCs into nonhuman primates (NHPs).Methods: Blood from O-type WT and TKO pigs was processed to produce pRBCs for transfusion, which were transfused or not into NHPs (n=4 per group: WT, TKO, and control) after 25% total blood volume withdrawal: their biological responses were compared. Hematological, biochemical, and immunological parameters were measured before, immediately after, and at intervals following transfusion. Two months later, a second transfusion was performed in three NHPs of the transfusion group.Results: Transfusion of both WT- and TKO-pRBCs significantly improved RBC counts, hematocrit, and hemoglobin levels up to the first day post-transfusion, compared to the controls. The transfusion groups showed instant complement activation and rapid elicitation of anti-pig antibodies, as well as elevated liver enzyme and bilirubin levels post-transfusion. Despite the higher agglutination titers with WT-pRBCs in the pre-transfusion crossmatch, the differences between the WT and TKO groups were not remarkable except for less impairment of liver function in the TKO group. After the second transfusion, more pronounced adverse responses without any hematological gain were observed.Conclusions: WT- and TKO-pRBC transfusions effectively increased hematologic parameters on the first day, with rapid clearance from circulation thereafter. However, pRBC transfusion triggers strong antibody responses, limiting the benefits of the pRBC transfusion and increasing the risk of adverse reactions.


  • Open Access

    Reference Intervals for Research Parameters of Reticulocyte Hemoglobin and Platelet Clumps in Healthy Korean Adults

    by Miyoung Kim, Sangkyoon Hong, Nan Young Kim, Kibum Jeon, Jiwon Lee, Han-Sung Kim, Hee Jung Kang, Young Kyung Lee

    Miyoung Kim, Sangkyoon Hong, Nan Young Kim, Kibum Jeon, Jiwon Lee, Han-Sung Kim, Hee Jung Kang, and Young Kyung Lee. Lab Med Qual Assur 2024;46:38-42. https://doi.org/10.15263/jlmqa.2024.46.1.38

  • Open Access

    Biological response of nonhuman primates to controlled levels of acute blood loss

    by Juhye Roh, Eun Mi Park, Haneulnari Lee, Jeong Ho Hwang, Hyung-Sun Kim, Jinyoung Park, Hee Jung Kang

    Introduction: The global shortage of human blood for medical use has prompted the development of alternative blood sources. Nonhuman primates (NHPs) are commonly used owing to their physiological similarities to humans. The objective of the current study was to establish a controlled-blood-loss model in NHPs to explore their clinical and biological responses.Methods: Blood was sequentially withdrawn from 10 cynomolgus monkeys (10, 14, 18, 22, and 25% of the total blood volume); their vital signs were monitored, and blood parameters were serially analyzed. Humoral mediators in the blood were measured using flow cytometry and enzyme-linked immunosorbent assays.Results: In NHPs subjects to 25% blood loss and presenting with related clinical symptoms, the systolic blood pressure ratio on day 0 after bleeding was significantly lower than that of the animals from the other groups (median: 0.65 vs. 0.88, P = 0.0444). Red blood cell counts from day 0–14 and hematocrit levels from day 0–7 were markedly decreased relative to the baseline (P < 0.01). These parameters showed a direct correlation with the extent of blood loss. The levels of creatine phosphokinase, aspartate aminotransferase, and alanine aminotransferase exhibited increases in response to blood loss and had a stronger correlation with the hemoglobin ratio than the volume of blood loss. The levels of C3a and C4a, as well as interleukin (IL)-1α and IL-15, displayed a strong correlation, with no apparent association with blood loss.Conclusion: The findings of the present study showed that only NHPs with 25% blood loss exhibited clinical decompensation and significant systolic blood pressure reduction without fatalities, suggesting that this level of blood loss is suitable for evaluating blood transfusion efficacy or other treatments in NHP models. In addition, the ratio of hemoglobin may serve as a more dependable marker for predicting clinical status than the actual volume of blood loss. Thus, our study could serve as a basis for future xenotransfusion research and to predict biological responses to massive blood loss in humans where controlled experiments cannot be ethically performed.


  • Open Access

    Initial investigation on the feasibility of porcine red blood cells from genetically modified pigs as an alternative to human red blood cells for transfusion

    by Sangkeun Park, Haneulnari Lee, Eun Mi Park, Juhye Roh, Pul Ip Kang, Joohyun Shim, Kimyung Choi, Hee Jung Kang

    The decline in blood donation rates and the ongoing shortage of blood products pose significant challenges to medical societies. One potential solution is to use porcine red blood cells (pRBCs) from genetically modified pigs as an alternative to human red blood cells (hRBCs). However, adverse immunological reactions remain a significant obstacle to their use. This study aimed to evaluate the compatibility of diverse genetically modified pRBCs with human serum. We acquired human complement-competent serum, complement 7 (C7)-deficient serum, and hRBCs from all ABO blood types. Additionally, we used leftover clinical samples from health checkups for further evaluation. pRBCs were collected from wild-type (WT) and genetically modified pigs: triple knockout (TKO), quadruple KO (QKO), and TKO/hCD55.hCD39 knockin (hCD55.hCD39KI). The extent of C3 deposition on RBCs was measured using flow cytometry after incubation in C7-deficient serum diluted in Ca++-enriched or Ca++-depleted and Mg++-enriched buffers. The binding of immunoglobulin (Ig) M/IgG antibody to RBCs after incubation in ABO-type human serum was evaluated using flow cytometry. Naïve human serum- or sensitized monkey serum-mediated hemolysis was also evaluated. Phagocytosis was assessed by incubating labeled RBCs with the human monocytic cell line THP-1 and measurement by flow cytometry. All three genetic modifications significantly improved the compatibility of pRBCs with human serum relative to that of WT pRBCs. The extent of IgM/IgG binding to genetically modified pRBCs was lower than that of WT pRBCs and similar to that of O-type hRBCs. Total and alternative pathway complement activation in all three genetically modified pRBCs was significantly weaker than that in WT pRBCs and did not differ from that in O-type hRBCs. The extent of serum-mediated hemolysis and phagocytosis of these genetically modified pRBCs was low and similar to that of O-type hRBCs. Sensitized monkey serum-mediated hemolysis in QKO and TKO/hCD55.hCD39KI pRBCs was higher than in O-type hRBCs but lower than in TKO pRBCs. The elimination of porcine carbohydrate antigens in genetically modified pigs significantly enhanced pRBC compatibility with naïve human sera, which was comparable to that of O-type hRBCs. These findings provide valuable insights into the development of pRBCs as potential alternatives to hRBCs.


  • Open Access

    Comparative transcriptome analysis between long- and short-term survival after pig-to-monkey cardiac xenotransplantation reveals differential heart failure development

    by Byeonghwi Lim, Min-Jae Jang, Seung-Mi Oh, Jin Gu No, Jungjae Lee, Sang Eun Kim, Sun A. Ock, Ik Jin Yun, Junseok Kim, Hyun Keun Chee, et al.

    Cardiac xenotransplantation is the potential treatment for end-stage heart failure, but the allogenic organ supply needs to catch up to clinical demand. Therefore, genetically-modified porcine heart xenotransplantation could be a potential alternative. So far, pig-to-monkey heart xenografts have been studied using multi-transgenic pigs, indicating various survival periods. However, functional mechanisms based on survival period-related gene expression are unclear. This study aimed to identify the differential mechanisms between pig-to-monkey post-xenotransplantation long- and short-term survivals. Heterotopic abdominal transplantation was performed using a donor CD46-expressing GTKO pig and a recipient cynomolgus monkey. RNA-seq was performed using samples from POD60 XH from monkey and NH from age-matched pigs, D35 and D95. Gene-annotated DEGs for POD60 XH were compared with those for POD9 XH (Park et al. 2021). DEGs were identified by comparing gene expression levels in POD60 XH versus either D35 or D95 NH. 1,804 and 1,655 DEGs were identified in POD60 XH versus D35 NH and POD60 XH versus D95 NH, respectively. Overlapped 1,148 DEGs were annotated and compared with 1,348 DEGs for POD9 XH. Transcriptomic features for heart failure and inhibition of T cell activation were observed in both long (POD60)- and short (POD9)-term survived monkeys. Only short-term survived monkey showed heart remodeling and regeneration features, while long-term survived monkey indicated multi-organ failure by neural and hormonal signaling as well as suppression of B cell activation. Our results reveal differential heart failure development and survival at the transcriptome level and suggest candidate genes for specific signals to control adverse cardiac xenotransplantation effects.


  • Open Access

    Overcoming Immunological Barriers in Xenotransplantation: A Historical Review of Previous Research and Future Directions

    by Hee Jung Kang

    Hee Jung Kang, M.D.. Lab Med Online 2023;13:275-81. https://doi.org/10.47429/lmo.2023.13.4.275

  • Open Access

    Recent trends in perioperative blood transfusion during elective kidney transplantation

    by Juhye Roh, Sangkeun Park, Hee Jung Kang

    Juhye Roh, Sangkeun Park, Hee Jung Kang. Korean J Transplant 2023;37:197-202. https://doi.org/10.4285/kjt.23.0041